A new ASCO-delivered analysis reports that AI-driven drug discovery has moved into measurable interventional human development, counting 117 AI-enabled therapeutic assets across 63 companies entering trials (with 60 completing Phase 1 and 8 completing Phase 2). The review highlights how AI discovery claims are difficult to verify using FDA records alone, but the clinical pipeline is increasingly visible. Among late-stage programs cited, Insilico Medicine’s TNIK inhibitor rentosertib (ISM001/INS018-055) reported Phase 2a efficacy signals in idiopathic pulmonary fibrosis in Nature Medicine, while the tracker also references fast-track progress for additional late-stage oncology assets. The summary points to accelerating clinical conversion for AI-designed modalities, along with governance issues around how AI involvement is categorized.